Alphatec (NASDAQ:ATEC) Stock Price Crosses Below 200-Day Moving Average After Earnings Miss

Alphatec Holdings, Inc. (NASDAQ:ATEC)’s share price passed below its 200-day moving average during trading on Friday following a weaker than expected earnings announcement. The stock has a 200-day moving average of $10.62 and traded as low as $6.81. Alphatec shares last traded at $7.04, with a volume of 27,294,109 shares.

The medical technology company reported $0.09 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). The business had revenue of $221.17 million during the quarter, compared to the consensus estimate of $225.16 million. Alphatec had a negative return on equity of 6,752.24% and a negative net margin of 10.35%. The firm’s revenue for the quarter was up 12.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.03 EPS.

More Alphatec News

Here are the key news stories impacting Alphatec this week:

• Positive Sentiment: Third-quarter revenue increased 12.6% year over year to approximately $221.2 million, while earnings of $0.09 per share improved from $0.03 a year earlier. Management continues to target a 16% adjusted EBITDA margin for 2026. Alphatec third-quarter results
• Positive Sentiment: Wells Fargo lowered its price target from $14 to $12 but maintained an “overweight” rating, implying substantial potential upside if Alphatec stabilizes growth and executes on its profitability plans. Wells Fargo rating
• Neutral Sentiment: Analyst expectations remain divided: BMO Capital Markets downgraded the stock to “market perform” with an $8 price target, while other analysts continue to see valuation upside. BMO Capital Markets rating
• Negative Sentiment: Alphatec reduced its 2026 revenue outlook to approximately $862 million from roughly $882 million, below the prior market expectation. Management cited fewer surgeons purchasing its bone-graft products used in spinal-fusion procedures. Alphatec guidance reduction
• Negative Sentiment: Third-quarter adjusted earnings of $0.09 per share and revenue of $221.2 million both missed analyst estimates, reinforcing concerns about slowing demand despite year-over-year growth. Alphatec earnings miss
• Negative Sentiment: Levi & Korsinsky and Ademi LLP announced investigations into potential securities-law violations related to Alphatec’s outlook and subsequent decline. These notices may add reputational and legal risk, although they do not establish wrongdoing. Alphatec investor investigation

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ATEC. JPMorgan Chase & Co. dropped their price target on shares of Alphatec from $16.00 to $15.00 and set an “overweight” rating on the stock in a report on Friday. Stephens began coverage on shares of Alphatec in a report on Thursday, July 23rd. They set an “overweight” rating and a $15.00 price objective for the company. TD Cowen lowered their price objective on shares of Alphatec from $13.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday. Stifel Nicolaus lowered their price objective on shares of Alphatec from $16.00 to $13.00 and set a “buy” rating on the stock in a research report on Wednesday, July 8th. Finally, UBS Group raised their target price on shares of Alphatec from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Twelve equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $16.60.

Insider Activity

In other Alphatec news, General Counsel Tyson Marshall sold 8,168 shares of the business’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $9.65, for a total transaction of $78,821.20. Following the completion of the sale, the general counsel directly owned 630,398 shares in the company, valued at $6,083,340.70. The trade was a 1.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Patrick Miles purchased 115,000 shares of Alphatec stock in a transaction dated Thursday, September 10th. The shares were acquired at an average cost of $8.81 per share, with a total value of $1,013,150.00. Following the transaction, the chief executive officer directly owned 5,893,551 shares in the company, valued at approximately $51,922,184.31. The trade was a 1.99% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 13.48% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Paradigm Capital Management Inc. NY purchased a new stake in Alphatec in the 2nd quarter worth approximately $9,413,000. Bank of America Corp DE lifted its holdings in Alphatec by 26.9% during the first quarter. Bank of America Corp DE now owns 2,560,971 shares of the medical technology company’s stock valued at $27,863,000 after purchasing an additional 543,059 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in Alphatec during the second quarter valued at approximately $3,092,000. Great Lakes Advisors LLC purchased a new position in Alphatec during the second quarter valued at approximately $2,423,000. Finally, Arrowstreet Capital Limited Partnership boosted its position in shares of Alphatec by 102.3% in the first quarter. Arrowstreet Capital Limited Partnership now owns 507,017 shares of the medical technology company’s stock worth $5,516,000 after purchasing an additional 256,342 shares during the period. 66.35% of the stock is currently owned by institutional investors.

Alphatec Price Performance

The stock’s 50-day simple moving average is $10.14 and its two-hundred day simple moving average is $10.62. The firm has a market capitalization of $1.09 billion, a P/E ratio of -12.80 and a beta of 0.78.

About Alphatec

Alphatec Holdings, Inc is a medical technology company focused on the design, development and commercialization of products and procedural solutions for spine surgery. The company aims to improve the treatment of spinal disorders through technologies that support spinal fusion, deformity correction, reconstruction and minimally invasive procedures.

Its portfolio includes spinal implants, surgical instruments, navigation and imaging technologies, and intraoperative monitoring solutions.